AstraZeneca Pharma India and Sun Pharmaceutical Industries have entered into a distribution services agreement for AstraZeneca’s brand Axcer, a new brand of ticagrelor in India.
Ticagrelor is a drug which is used for the treatment of acute coronary syndrome(ACS).
Sanjay Murdeshwar, the Managing Director of AstraZeneca Pharma said, “Ticagrelor works by preventing the formation of new blood clots and maintains blood flow in the body, helping reduce a patient’s risk of another heart attack or cardiovascular-related death.”